Form 4: HeartBeam Director Ferrari Granted 50,000 RSUs

HeartBeam, Inc. Director Richard Ferrari was granted 50,000 restricted stock units, vesting in two tranches by June 2026.

Summary

• Richard Ferrari, a Director and 10% owner of HeartBeam, Inc. (BEAT), was granted 50,000 restricted stock units (RSUs).
• The grant occurred on February 9, 2026, as a "Special RSU" under the company's 2022 Equity Incentive Plan.
• These RSUs will vest in two equal tranches: 25,000 shares on March 31, 2026, and the remaining 25,000 shares on June 30, 2026.
• The vesting commencement date for these RSUs was January 1, 2026.
• Following this transaction, Ferrari beneficially owns 229,136 shares directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting continued insider alignment and a standard compensation practice, without indicating any immediate operational changes or significant financial events.

Positives

• The grant of 50,000 restricted stock units to Director Richard Ferrari aligns his interests with long-term shareholder value.
• Issuance from the 2022 Equity Incentive Plan indicates a structured approach to executive compensation and retention.

Negatives

• The grant of RSUs at a $0 price, while standard for such awards, represents potential dilution upon vesting if not offset by other share management strategies.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that RSU grants to directors are a common practice in the biotechnology and medical device sectors, like HeartBeam, Inc., to incentivize long-term commitment and align leadership interests with shareholder returns, especially for companies in growth or development phases.

Comparison to Industry Standards

• The grant of 50,000 RSUs to a director is within the typical range for non-executive directors at small to mid-cap medical technology companies, comparable to grants seen at peers such as ElectroCore, Inc. (ECOR) or BioSig Technologies, Inc. (BSGM) for similar roles, though the specific value depends on the company's market capitalization and compensation philosophy.
• The vesting schedule, with tranches over a six-month period, is relatively short compared to typical multi-year vesting schedules for executive performance-based awards, but can be common for director retention or special grants.

Corporate Governance

Related Party Transactions

• The RSU grant to Richard Ferrari, a Director and 10% owner, constitutes a related party transaction, which is a standard compensation practice disclosed via Form 4.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting, but also increased alignment of a key director's interests with long-term share price performance.
• Management/Directors: Richard Ferrari's compensation package is enhanced, incentivizing his continued involvement.

Next Steps

• First tranche of 25,000 RSUs will vest on March 31, 2026.
• Second tranche of 25,000 RSUs will vest on June 30, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine RSU grant to a director, which is a standard compensation practice and does not present new information that would fundamentally alter the investment thesis for HeartBeam, Inc. It indicates continued insider alignment but does not provide catalysts for a strong buy or sell recommendation.

Keywords

HeartBeam, BEAT, Richard Ferrari, Form 4, SEC Filing, Restricted Stock Units, RSU Grant, Insider Transaction, Director Compensation, Equity Incentive Plan, Beneficial Ownership